Clinical trials
Immune Checkpoint Inhibitors (ICIs) clinical trials
Below are recruiting immune checkpoint inhibitors (icis) clinical trials, each written for real people, not researchers. We’re tracking 70 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05726396RecruitingPhase 2
Microbiome therapy for steroid-resistant immune colitis
This Phase 2 pilot study tests a “restorative microbiota therapy” (RMT) to treat colitis caused by immune checkpoint inhibitors when standard treatments like steroids are not working. It aims to see if this approach is safe and practical, and may improve diarrhea and gut inflammation.
Brainerd, MinnesotaAges 18 years+ - NCT04974671RecruitingPhase 2
SBRT radiation for limited cancer growth on immunotherapy
This trial tests whether targeted external-beam radiation (SBRT) can control a small number of progressing kidney cancer spots while you continue immune checkpoint inhibitor immunotherapy. It may help shrink or stop those specific “oligoprogressive” lesions and prolong benefit from your current immunotherapy.
New Haven, ConnecticutAges 18 years+ - NCT06388031RecruitingPhase 2
Re-trying immunotherapy for advanced lung cancer after long-term success
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
BeijingAges 18–80 - NCT07644715Recruiting
AI Analysis of Heart Rhythms and Immune-Related Heart Damage
This study uses artificial intelligence to analyze heart electrical recordings (ECGs) from existing patient databases to better detect dangerous heart rhythm problems and heart inflammation caused by cancer immunotherapy. Researchers are not giving any new treatments—they're studying existing data to improve diagnosis.
ParisAges Any age - NCT06470971RecruitingPhase 2
Siltuximab to prevent severe side effects during immunotherapy rechallenge
This trial tests if siltuximab can prevent severe immune-related side effects when patients restart immunotherapy (anti-PD-1/PD-L1) after previous severe side effects. It aims to make rechallenge safer for people with advanced cancer.
Columbus, OhioAges 18 years+ - NCT05834413Recruiting
Herbs plus chemo and immunotherapy to prevent lung cancer spread
This study looks at whether staged Chinese herbal medicine added to standard treatment can lower the risk of lung cancer coming back or spreading after surgery. It is for people with stage Ib to IIIb non-small cell lung cancer whose tests show no “driver gene” targets.
Shanghai, Shanghai MunicipalityAges 18–74 - NCT06446154RecruitingPhase 2
Fruquintinib after immunotherapy for advanced liver cancer
This trial tests a new drug called fruquintinib for people with advanced liver cancer who have already tried immunotherapy. It may help shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18 years+ - NCT06502691RecruitingPhase 1/Phase 2
New imaging test to measure PARP in metastatic breast cancer
This trial tests a new imaging scan called [18F]FTT PET that may show how much of a protein called PARP is in your tumors. This could help doctors decide if a PARP inhibitor (a type of targeted therapy) is right for you. You may be able to join if you have metastatic breast cancer and are already planning to take a PARP inhibitor.
Seattle, WashingtonAges 18 years+ - NCT06037811RecruitingPhase 2
Adalimumab for Immunotherapy-Related Arthritis
This study tests if a medicine called adalimumab (a type of TNF blocker) can help with new joint pain and swelling (inflammatory arthritis) caused by some immunotherapy drugs. It aims to reduce the need for high-dose steroids and improve symptoms.
London, OntarioAges 18 years+ - NCT06841705RecruitingPhase 2
Early vedolizumab as first treatment for colitis from immunotherapy
This trial tests if giving vedolizumab early can help control severe diarrhea and colon inflammation caused by immunotherapy (a type of cancer treatment). It may offer a new option for people who develop these side effects.
Boston, MassachusettsAges 18 years+ - NCT04294771Recruiting
Heart problems linked to cancer immunotherapy drugs
This study looks at reports from large health databases to find out if certain cancer drugs (checkpoint inhibitors) cause heart problems. It aims to understand which patients have a higher risk, which may help doctors watch for heart issues in the future.
ParisAges Any age - NCT04954599RecruitingPhase 1/Phase 2
CP-506 for hard-to-treat cancers with DNA repair defects
This Phase 1/2 study tests CP-506 in people with advanced solid tumors that have specific DNA repair problems (homologous recombination or Fanconi anemia-related defects). It may be used alone or combined with carboplatin or an immune therapy, aiming to shrink tumors or improve control when standard options are limited.
BrusselsAges 18 years+ - NCT07759856RecruitingPhase 2
Natural killer cells plus immunotherapy for small cell lung cancer
This trial tests combining natural killer (NK) cells with an immunotherapy drug as a maintenance treatment after standard chemotherapy for small cell lung cancer that has spread. The goal is to see if this combination can help keep the cancer from growing.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07339488RecruitingPhase 2
Low-dose radiation and immunotherapy to shrink hard-to-remove esophageal cancer
This trial tests a treatment approach that combines low-dose radiation with immunotherapy and chemotherapy for people with esophageal cancer that is hard to remove with surgery. The goal is to shrink the tumor enough to make surgery possible, which could improve outcomes.
Shantou, GuangdongAges 18–75 - NCT07249060Recruiting
Interferon levels in cancer and autoimmune disease patients
This study looks at a protein called interferon in the blood of people with cancer who are starting immunotherapy, and people with certain autoimmune diseases (such as lupus, Sjögren's syndrome, scleroderma, or inflammatory myopathy). The goal is to compare interferon patterns and better understand immune responses.
Pamplona, NavarreAges 18 years+ - NCT06487663Recruiting
TACE plus immunotherapy for untreated liver cancer
This study tests combining TACE (a procedure to block the tumor's blood supply) with immunotherapy drugs for liver cancer that has not spread outside the liver. It is for people who have not had any prior treatment for their liver cancer and are healthy enough for TACE.
TianjinAges 18–75 - NCT07754409Recruiting
Quality of life during lung cancer treatment with immunotherapy
This study looks at how patients with advanced lung cancer feel during their treatment, which combines chemotherapy, radiation, and an immunotherapy drug. The goal is to understand and improve quality of life during therapy.
GothenburgAges 18 years+ - NCT07705438Recruiting
PET scan to predict if immunotherapy works in TNBC
This trial tests a new type of PET scan (Granzyme B-PET) to see if it can predict how well immunotherapy will work for people with triple-negative breast cancer that has spread. If it works, doctors might be able to tell sooner whether treatment is helping.
ShanghaiAges 18 years+ - NCT07683975RecruitingPhase 4
Infliximab for kidney injury caused by immunotherapy
This study tests whether infliximab can treat kidney damage caused by immune checkpoint inhibitor cancer therapy. It aims to see if this medication helps patients recover kidney function after injury from their cancer treatment.
Boston, MassachusettsAges 18 years+ - NCT07639138RecruitingPhase 2
Lenalidomide with targeted therapy and immunotherapy for advanced liver cancer
This trial tests whether adding lenalidomide (a drug that boosts the immune system) to your current targeted therapy and immunotherapy can help advanced liver cancer that has progressed after previous treatments. You would be eligible if your cancer has already been treated with at least two prior drug combinations and initially responded before growing back.
Beijing, No. 1 Shuaifuyuan, Dongcheng District, Beijing, ChinaAges 18–75 - NCT07574047RecruitingPhase 2
Immunotherapy at different times of day for advanced melanoma
This trial tests whether giving immunotherapy at different times of the day (chrono-immunotherapy) is better for people with advanced melanoma. It looks at how timing might affect how well the treatment works and side effects.
Fribourg, Canton of FribourgAges 18 years+ - NCT06730503Recruiting
Glycoprotein test for lung cancer immunotherapy response
This study looks at whether certain glycoproteins in your blood can help predict how well immunotherapy works for advanced non-small cell lung cancer. You would give blood samples before and after starting an immune checkpoint inhibitor treatment.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07405086RecruitingPhase 4
Morning versus afternoon immunotherapy for advanced cancer
This trial tests whether getting your immunotherapy infusion in the morning or in the afternoon makes any difference in how well it works. If you have certain types of advanced cancer and are about to start a standard FDA-approved immunotherapy, this study may help you and others by finding the best time of day for treatment.
Portland, OregonAges 18 years+ - NCT07138222Recruiting
Immune therapy and fertility in women and men with melanoma
This study looks at how immune checkpoint inhibitors (a type of immunotherapy) affect fertility and hormone health in premenopausal women and men with melanoma. It aims to understand and manage these side effects while you receive treatment.
Sydney, New South WalesAges 18–60
Hear when a new Immune Checkpoint Inhibitors (ICIs) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for immune checkpoint inhibitors (icis)?
- Yes. Clin2 currently lists 70 recruiting immune checkpoint inhibitors (icis) studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a immune checkpoint inhibitors (icis) trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a immune checkpoint inhibitors (icis) trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.